ST. Joseph's - Camillus is a medicare approved dialysis facility center in Camillus, New York and it has 11 dialysis stations. It is located in Onondaga county at 5101 West Genesee Street, Camillus, NY, 13031. You can reach out to the office of ST. Joseph's - Camillus at (315) 488-2979. This dialysis clinic is managed and/or owned by Fresenius Medical Care. ST. Joseph's - Camillus has the following ownership type - Profit. It was first certified by medicare in July, 2009. The medicare id for this facility is 332666 and it accepts patients under medicare ESRD program.
| Name | ST. Joseph's - Camillus |
|---|---|
| Location | 5101 West Genesee Street, Camillus, New York |
| No. of Dialysis Stations | 11 |
| Medicare ID | 332666 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 5101 West Genesee Street, Camillus, New York, 13031 | |
| (315) 488-2979 | |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
| NPI Number | 1265462386 |
| Doing Business As | St Joseph's Hospital Health Center |
| Address | 5101 West Genesee Street Camillus, New York, 13031 |
| Phone Number | (315) 488-2979 |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
| NPI Number | 1548407943 |
| Organization Name | St. Joseph's - Camillus |
| Doing Business As | Sjls, Llc |
| Address | 5101 W Genesee St Camillus, New York, 13031 |
| Phone Number | (315) 488-2979 |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 61% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 17% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 22% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 56% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 34% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 14% |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 58% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 25% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 17% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 57% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 35% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 8% | 12% |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 80% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 20% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 74% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 12% |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 44 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 11 |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 72 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 604 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at ST. Joseph's - Camillus with elevated calcium levels.
| Patients with hypercalcemia | 76 |
| Hypercalcemia patient months | 630 |
| Patients with Serumphosphor | 80 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 30 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 29 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 74 |
| Patient months included in arterial venous fistula and catheter summaries | 560 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 78 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 9 |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 66 |
| Hospitalization Rate in facility | 111.6 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 230.6 |
| Hospitalization Rate: Lower Confidence Limit | 56.2 |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at ST. Joseph's - Camillus were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 42.1 (Worse than Expected) |
| Readmission Rate: Upper Confidence Limit | 61.4 |
| Readmission Rate: Lower Confidence Limit | 25.8 |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at ST. Joseph's - Camillus get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .48 (As Expected) |
| SIR: Upper Confidence Limit | 1.59 |
| SIR: Lower Confidence Limit | .08 |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether ST. Joseph's - Camillus's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 55 |
| Transfusion Rate in facility | 5.4 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 65.8 |
| Transfusion Rate: Lower Confidence Limit | .6 |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
The rate of mortality show you whether patients who were being treated regularly at ST. Joseph's - Camillus lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 253 |
| Mortality Rate in facility | 17.3 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 23.5 |
| Mortality Rate: Lower Confidence Limit | 12.4 |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago
ST. Joseph's - Camillus Location: 5101 West Genesee Street, Camillus, New York, 13031 Phone: (315) 488-2979 |
News Archive
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.
Misys PLC, a global provider of application software and services for the banking and financial industry, has announced that the National Bank of Abu Dhabi will deploy its commercial lending solution, Misys Loan IQ, for its loan operations.
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
› Verified 1 days ago